Certain Drugs May Boost Weight Loss After RYGB

Roux-en-Y gastric bypass (RYGB) typically leads to substantial, long term weight loss (WL) and diabetes remission, though there is a wide variation in response to RYGB among individual patients. Defining the pathways through which RYGB works should aid in the development of less invasive anti-obesity treatments, while identifying weight regulatory pathways unengaged by RYGB could facilitate the development of therapies that complement the beneficial effects of surgery.

READ FULL ARTICLE From press.endocrine.org